Lyell Immunopharma (LYEL) Stock Statistics & Valuation Metrics

Lyell Immunopharma has a market cap or net worth of $405.90M. The enterprise value is $30.12M.

Lyell Immunopharma has 21,218,218 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lyell Immunopharma’s return on equity (ROE) is -0.90 and return on invested capital (ROIC) is -79.19%.

The current PE Ratio of Lyell Immunopharma is ―. Lyell Immunopharma’s PEG ratio is -0.24.

In the last 12 months, Lyell Immunopharma had revenue of 61.00K and earned -342.99M in profits. Earnings per share was -1.31.

In the last 12 months, operating cash flow was -165.01M and capital expenditures -520.00K, giving a free cash flow of -165.53M billion.

Lyell Immunopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Lyell Immunopharma upcoming earnings date is Mar 4, 2026, After Close (Confirmed).

Lyell Immunopharma as a current ratio of 7.06, with Debt / Equity ratio of 15.59%

In the past 12 months, Lyell Immunopharma has paid 0.00 in taxes.

Lyell Immunopharma EV to EBITDA ratio is -16.45, with an EV/FCF ratio of -20.26.

Lyell Immunopharma has $319.62M in cash and marketable securities with $44.28M in debt, giving a net cash position of $275.34M billion.

Gross margin is 100.00%, with operating margin of -588122.95%, and net profit margin of -562285.25%.

The average price target for Lyell Immunopharma is $20.00, which is 11.43% higher than the current price. The consensus rating is Hold